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ABSTRACT
Brain metastases are uncommon localizations in epithelial ovarian cancer 
(EOC), their reported incidence is increasing and no predictive biomarkers have been 
identified yet. Goals of this study were: i) to define a possible association between 
Estrogen Receptor (ER), Progesterone Receptor (PR), Androgen Receptor (AR),human 
EGF receptor 2 (HER2) and brain progression in EOC patients, and ii) to identify 
differences in ER, PR, AR and HER2 protein expression from primary EOC and its 
matched resected brain metastasis. A retrospective series of 11 EOC with matched 
brain metastasis surgically removed was collected. For comparison, a “Control 
dataset” of 22 patients, without evidence of brain involvement after an adequate 
follow up was matched. ER, PR, AR and HER2 status were analyzed by means of 
immunohistochemistry forCases (both primary and metastatic lesions) and Controls.
Univariate analysis showed that AR status was significantly associated with 
brain localization, both considered as discrete variable (cut-off: 10%, p=0.013) and 
as continuous one (p=0.035). Multivariate analysis confirmed this trend (p=0.053). 
When considered as continuous variables, ER and AR showed greater expression 
in primary tumors in comparison with brain metastases (p=0.013 and p=0.032, 
respectively).
In our series, AR predicts brain involvement, with a 9.5 times higher propensity 
for AR-negative EOC. Moreover, brain dissemination is probably the result of 
progressive dedifferentiation of primary tumor, shown by reduction of ER and AR 
expression in metastases. Further studies are required, in order to anticipate and 
improve multimodal treatment of brain metastases.
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 25), pp: 41143-41153
       Research Paper
Oncotarget41144www.impactjournals.com/oncotarget
INTRODUCTION
Epithelial ovarian cancer (EOC) is the first cause of 
death among women with gynaecological malignancies 
[1]. In its natural history, this tumor tends to remain 
localized in the abdomen and pelvis even in advanced 
stage of disease, whereas haematogenous spread is a 
late event [2]. In fact, distant metastases account for 
approximately 16% of cases, and pleura (33%), liver 
(26%) and lung (3%) are the most common sites of 
tumor progression [3]. Central nervous system (CNS) 
involvement is a very uncommon and late event with an 
incidence ranging from 0.29 to 12% according to different 
series [3-6]. More recently, an increase in metastatic CNS 
involvement has been reported [5, 7, 8],probably reflecting 
prolonged patients’ survival related to improved surgery, 
radiotherapy and medical treatments [3, 4, 6, 8-14]. Several 
favorable prognostic factors have been identified such as 
younger age at time of diagnosis, Karnofsky PS, absence 
of extracranial lesions or solitary brain lesion [4, 6, 8-14]. 
However, prognosis remains globally unfavourable with 
a median overall survival (OS) of about 9.6 months for 
patients treated with only best supportive care, and 20.5 
months for those undergoing multimodal treatments [13]. 
Clearly, early detection of CNS involvement may enhance 
the possibility of successfully treating these patients.
Hormonal receptor status (Estrogen Receptor-ER, 
Progesterone Receptor-PR and Androgen Receptor-AR) 
and Epidermal growth factor receptor 2 (HER2) status 
have been widely investigated as potential prognostic 
parameters in EOC patients, but reported results are 
controversial [15-22].
The aims of our study were the following: i) to 
define a possible association between ER, PR, AR, 
andHER2 with CNS progression in EOC patients, and ii) 
to identify differences in ER, PR, AR and HER2 protein 
expression from primary EOCs and their matched resected 
brain metastases.
RESULTS
Patients
Case dataset. The clinical and pathological features 
of primary ovarian lesions of the Case dataset are 
summarized in Table 1. Briefly, patient’s median age was 
61 years and according to the FIGO classification there 
were 2/11 (18%) stage II, 6/11 (55%) stage III, and 3/11 
(27%) stage IV patients. Up-front surgery was performed 
in 9 cases (82%) and in 7 patients (64%) a macroscopic 
residual tumor was assessed; most of the cases were high-
grade serous adenocarcinoma with solid and papillary 
features (82%). All patients underwent adjuvant platinum-
based chemotherapy. At the time of statistical analysis 
(June 2016), 3 of 11 (27%) patients were alive, whereas 
the remaining 7 patients (64%) had died; one patient was 
lost. The first site of relapse was brain in 7/11 (64%) cases, 
followed by lymph node (3/11, 27%); other sites included 
liver and mediastinum. All patients developed a CNS 
metastasis (median age: 62 years) with a median bPFS of 
23 months (range 11-68). The majority of cases showed a 
single CNS metastasis (73%, 8/11) localized in cerebral 
hemispheres and, specifically, frontal lobe represented 
the most common localization (45%, 5/11). Surgical CNS 
treatment consisted of gross total or incomplete resection 
followed by systemic chemotherapy (Pegylated liposomal 
doxorubicin and Vinorelbine, oral Topotecan, Pegylated 
liposomal doxorubicin alone, Carboplatinum and 
Gemcitabine)in 4 patients (36%), loco-regional treatments 
as Whole Brain Radiotherapy (WBRT) in 64% (7/11) and 
stereotactic radiotherapy in 9% of cases (1/11). The bOS 
was 7 months (range 3-64). Table 2 reports the clinical 
parameters of the 11 cases with CNS metastases.
Control dataset. This subgroup included 22 patients 
with a median age at primary ovarian cancer diagnosis of 
65.5 years (range 36-76). At diagnosis, 12/22 presented 
a FIGO stage III (55%), 6/22 (27%) a FIGO stage 
IV and 4/22 (18%) a FIGO stage II. All patients had a 
histological diagnosis of serous ovarian cancer. Twelve out 
of 22 (55%) cases underwent neoadjuvant platinum-based 
chemotherapy (NACT) followed by Interval Debulking 
Surgery (IDS); the remaining cases had up-front surgery; 
in 15/22 patients (68%) the surgery resulted suboptimal 
with a macroscopic residual tumor. All patients underwent 
adjuvant platinum-based chemotherapy. Seventeen (77%) 
patients experienced a progression disease with a median 
PFS of 16 months (range 4-73). Specifically, the most 
frequent sites of relapse were peritoneum and/or lymph 
nodes (88%, 15/17). The OS was 38.5 months (range 6-82) 
and, at the time of statistical analysis, 13/22 (59%) patients 
were dead. Table 1 resumes the main clinico-pathological 
features of Control dataset.
The two subgroups (Case and Controls)resulted 
homogeneous and comparable. There were not statistically 
significant differences for age (p = 0,323), tumor grade 
(p=1), stage of disease (p=1), type of surgery (p= 0,067), 
histotype (p=0,12) residual disease after surgery (p=0.9), 
(Table 1).
Immunohistochemical results
All cases of both datasets were evaluated by 
immunohistochemistry, but we had necessarily to exclude 
one case of primary ovarian cancer in the Case dataset 
as patient underwent NACT with a good pathological 
tumor response (only a sub-millimetric focus of 
residual carcinoma was found on histological specimen, 
insufficient to correctly evaluate immune-histochemical 
analyses). Table 3a reports immune-histochemical results 
of Case (both primary and CNS metastasis) and Control 
dataset, considered as dichotomized variables, whereas 
Table 3b and Table 4 as continuous variables.
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Table 1: Clinico-pathological features of primary ovarian lesion: “Case dataset” vs. “Control dataset”
Clinico-histopathological parameters Case datasetN=11 (%)
Control dataset
N=22 (%) p
Age, median (years) [range] 61 [44-72] 65.5 [36-76] 0.323
Histological type
 Serous 9 (82) 22 (100)
0,12
 Endometrioid 2 (18) 0 (0)
Histological grade
 G2 1 (9) 2 (9)
1
 G3 10 (91) 20 (91)
FIGO Stage
 II 2 (18) 4 (18)
1 III 6 (55) 12 (55)
 IV 3 (27) 6 (27)
Type of surgery
 Up-front 9 (82) 10 (45)
0.067
 Neoadjuvant CT + IDS 2 (18) 12 (55)
Macroscopic residual tumor
 Present 7 (64) 15 (68)
0.9 Absent 3 (27) 7 (32)
 Not available 1 (9) 0 (0)
First-line chemotherapy
 Platinum-based 11 (100) 22 (100)
1
 Other 0 (0) 0 (0)
Relapse
 Present 11 (100) 17 (77)
0.143
 Absent 0 (0) 5 (23)
First site of relapse
 Brain 7 (64) 0 (0)
0.001 Lymph nodes and/or 3 (27) 15 (88)*
 peritoneum other 1 (9) 2 (12) *
Patient’s status
 Alive 3 (27) 9 (41)
0.301 Dead 7 (64) 13 (59)
 Not available 1 (9) 0 (0)
PFS, median (months) [range] 22 [7-50] 16 [4-73]
OS, median (months) [range] 47 [17-110] 38.5 [6-82]
* In 5 patients a progression disease was not evident.
IDS: Interval Debulking Surgery; CT: Chemotherapy; PFS: Progression Free Survival; OS: Overall Survival.
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Figure 1 shows the immune-histochemical profile of 
a representative case of serous ovarian carcinoma included 
in the Case dataset (Case 11, Table 2) and its matched 
brain metastasis of one.
Statistical analysis
Case dataset vs. Control dataset. Using a cut-
off of 10%, only AR showed a significant difference of 
expression (p=0.013) between the two studied series: 
the risk to develop a brain metastasis appeared 9.5 times 
greater in patients with AR-negative primary ovarian 
cancer (Table 3a). Although at the limit for a statistical 
significant correlation, the HER2 expression in primary 
ovarian lesions was lower in patients who developed brain 
metastasis (p=0.069) (Table 3a). When considered as a 
continuous variable, AR retained its predictive role (mean 
Case dataset: 16.9; mean Control dataset: 40.5; p=0.035), 
as mainly expressed in primary ovarian tumors in the 
Control dataset (Table 3b). None of the other immune-
histochemical biomarkers proved to be statistically 
significant (Table 3a and 3b). Cox multivariate analysis 
confirmed the lack of AR tumor expression in primary 
ovarian lesions as a negative independent prognostic 
parameter, supporting brain metastasis progression 
(p=0.053, CI 95% 1.000-1.073).
Primary ovarian cancers vs. matched brain 
metastases. No statistical differences were observed 
when biomarkers were considered as dichotomized 
variables (Table 3a). However, if considered as continuous 
variables, ER and AR showed a statistically significant 
greater expression in primary tumors in comparison 
with brain metastases (p=0.013, CI 95%=6.16-40.65 and 
p=0.032, CI 95%=1.12-19.08 respectively) (Table 4). 
Figure 2 shows the immunohistochemical profile of AR in 
primary and metastatic brain lesions of our “Case dataset”.
DISCUSSION
Currently small retrospective studies suggest that 
histology, stage of disease [13], loss of BRCA1 function 
Table 2: Clinical parameters of 11 brain metastases included in the study
Cases Age bPFS (months)
Neurological 
symtoms
Number of 
brain lesion Site of brain lesion
Treatment of 
brain metastases bOS (months)
1 49 11 NA 1 Parietal lobe Surgery, Chemotherapy 6
2 57 68 Confusional state 1 Occipital lobe Surgery 42
3 70 29 Ataxia 1 Parieto-occipital lobe Surgery WBRT 41
4 70 22 Unilateral symptoms 1 Parietal lobe
Surgery 
Chemotherapy 
WBRT
6
5 50 18 Headache, vertigo 2 Temporo-occipital 
lobe, frontal lobe
Surgery 
Chemotherapy 
WBRT
29
6 70 28
Aphasia, 
disorientation, 
dizziness
1 Parietal lobe
Surgery, 
stereotactic 
radiotherapy
56
7 52 54 NA 1 Frontal lobe
Surgery 
Chemotherapy 
WBRT
7
8 62 15 Headache, altered 
walking gait
5
Temporal lobe, 
frontal lobe, 
occipital lobe
Surgery WBRT 3
9 46 23 NA 1 NA Surgery 3
10 72 18 Ataxia, dysmetria 6 Frontal lobe (the 
major)
Surgery WBRT 7
11 74 25 Vertigo 1 Frontal lobe Surgery WBRT 64
NA: not available; WBRT: Whole Brain Radiotherapy; bPFS: Progression Brain Metastasis Free Survival; bOS: Brain 
Metastasis Overall Survival.
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Table 3a: Immunohistochemical results for hormonal receptors (ER, PR, AR categorised as dichotomised variables) 
and HER2 in Case dataset (both primary and metastatic lesions) and Control dataset: statistical analysis
Immunohistochemistry Cut-off
Case dataset-
primary 
ovarian 
tumors 
N/10* (%)
Case 
dataset-
brain 
metastases 
N/11 (%)
Control 
dataset- 
primary 
ovarian 
tumors 
N/22 (%)
p (Cases vs. 
Controls: 
IHC 
comparison)
OR 
(Cases 
vs. 
Controls) 
(IC 95%)
p (Cases: 
primary vs. 
metastatic 
lesions: IHC 
comparison)
ER < 1% 1 (10) 2 (18) 1 (5)
p=0.534 p=0.200
≥ 1% 9 (90) 9 (82) 21 (95)
< 10% 1 (10) 3 (27) 2 (9)
p=1.000 p=0.300
≥ 10% 9 (90) 8 (73) 20 (91)
IRS ≤ 2 1 (10) 4 (36) 2 (9)
p=1.000 p=0.400
IRS > 2 9 (90) 7 (64) 20 (91)
PR < 1% 7 (70) 9 (82) 11 (50)
p=0.446 p=1.000
≥ 1% 3 (30) 2 (18) 11 (50)
< 10% 7 (70) 10 (91) 13 (59)
p=0.703 p=0.300
≥ 10% 3 (30) 1 (9) 9 (41)
IRS ≤ 2 7 (70) 10 (91) 13 (59)
p=0.703 p=0.300
IRS > 2 3 (30) 1 (9) 9 (41)
AR < 1% 3 (30) 6 (55) 2 (9)
p=0.293 p=1.000
≥ 1% 7 (70) 5 (45) 20 (91)
< 10% 6 (60) 8 (73) 3 (14)
p=0.013 9.5 (1.64 
- 54.99
p=0.133
≥ 10% 4 (40) 3 (27) 19 (86)
IRS ≤ 2 7 (70) 10 (91) 10 (45)
p=0.265 p=0.300
IRS > 2 3 (30) 1 (9) 12 (55)
HER2 0 9 (90) 7 (64) 14 (63)
p=0.069 1.6 (0.15 
- 17.22)
p=0.364
1+ 0 (0) 3 (27) 5 (23)
2+ 0 (0) 1 (9) 3 (14)
3+ 1 (10) 0 (0) 0 (0)
* one case was excluded due the limited neoplastic tissue available.
ER: Estrogen Receptor; PR: Progesterone Receptor; AR: Androgen Receptor; HER2: Human Epidermal Growth Factor 
Receptor 2; IRS: Immunoreactive Score; OR: Odds Ratio.
Table 3b: Immunohistochemical results for hormonal receptors (ER, PR, AR considered as continuous variables) in 
Case dataset and Control dataset: statistical analysis
Immunohistochemical 
parameters
Case vs. Control 
dataset N Mean Median Range p
ER Cases 10 57.4 62.5 0-95
p=0.397
Controls 22 67.1 75 0-95
PR Cases 10 6.5 0 0-35
p=0.442
Controls 22 11.5 0.5 0-75
AR Cases 10 16.9 6.5 0-65
p=0.035
Controls 22 40.5 32.5 0-90
ER: Estrogen Receptor; PR: Progesterone Receptor; AR: Androgen Receptor.
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[23], MDR-1 tumor expression [24] may be associated 
with CNS progression in very small series of patients. In 
the present study we investigated the predictive role of 
AR, ER, PR and HER2.
Hormone receptor status has been extensively 
investigated in EOC patients, playing an important role 
in ovarian cancer pathogenesis [25], but the literature data 
appear still conflicting and above all not conclusive [15-
22]. In a recent review, including 35 studies investigating 
the prognostic role of hormone receptors in EOC, ER 
failed to predict patients’ outcome, whereas elevated levels 
of PR and HER2 predicted favorable and worse survival, 
respectively [26]. AR tumor expression has been recently 
suggested to be a favourable prognostic parameter in 
Table 4: Immunohistochemical results for hormonal receptors (ER, PR, AR considered as continuous variables) in 
the Case dataset - primary vs. metastatic lesions: statistical analysis
Immunohistochemical 
parameters
Primary tumor vs. brain 
metastasis
Mean Median Range p
ER Primary tumor 57.4 62.5 0-95
p=0.013
Brain metastasis 34 22.5 0-76
PR Primary tumor 6.5 0 0-35
p=0.396
Brain metastasis 3.1 0 0-30
AR Primary tumor 16.9 6.5 0-65
p=0.032
Brain metastasis 6.8 0 0-35
ER: Estrogen Receptor; PR: Progesterone Receptor; AR: Androgen Receptor.
Figure 1: Case 11 of the “Case dataset”: representative case of a serous high-grade ovarian cancer (A-E) (A: H&E, 
10x): hormonal receptor status (B: ER=60%, 10x; C: PR=0%, 10x; D: AR=8%, 10x) and HER2tumor expression (E: 
HER2 3+, 10x). Its derived brain resected metastasis (F-J) with the same morphological appearance (F: H&E, 10x): hormonal receptor 
status (G: ER=72%, 10x; H: PR=0%, 10x; I: AR=5%, 10x) and HER2 metastasis expression (J: HER2 2+, 10x).
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Figure 2: AR tumor expression in primary and metastatic lesions of our “Case dataset”. From Case 1 to Case 10 (A, C: 
H&E, 10x/B-D: AR, 10x, Case 1; E, G: H&E, 10x/F, H: AR, 10x, Case 2; I, K: H&E, 10x/J, L: AR, 10x, Case 3; M, O: H&E, 10x/N, P: 
AR, 10x, Case 4; Q, S: H&E, 10x/R, T: AR, 10x, Case 5; U, W: H&E, 10x/V, X: AR, 10x, Case 7; Y, AA: H&E, 10x/Z-, AB: AR, 10x, 
Case 8; AC, AE: H&E, 10x/AD, AF: AR, 10x, Case 9; AG, AI: H&E, 10x/AH, AJ: AR, 10x, Case 10). Case 6 is not showed as excluded 
from the immunohistochemical analysis, due to insufficient residual cancer after neoadjuvant chemotherapy.
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serous EOCs, especially when co-expressed with PR [27, 
28]. Notably, AR is the only hormone receptor included in 
the five good-prognosis predictors of the protein-driven 
index of ovarian cancer (PROVAR), a protein-based panel 
able to predict time to EOC recurrence [29]. Due to the 
limited number of events, in the subgroup of EOC patients 
who developed CNS progression, hormonal receptor 
status role has not yet widely been explored.
In our case-control study, comparing patients 
who developed a CNS metastasis and patients who did 
not, we highlight a predictive role of AR. Specifically, 
patients with AR-negative EOC show a 9.5 times greater 
propensity to develop CNS metastases than AR-positive 
EOC (cut-off: 10%); moreover, when considered as 
continuous variable, AR retains its predictive value. 
Multivariate analysis confirms reduced AR expression 
in primary EOC as a negative independent predictive 
parameter. In a previous study, AR status has been reported 
to be associated with a prolonged ovarian cancer specific 
survival, underlining its favourable prognostic role [27], 
but our paper, for the first time, describe its predictive 
value in the subgroup of EOC metastatic to the brain. In 
the literature, different cut-off values have been considered 
in assessing the hormone receptor status positivity [16, 
17, 22, 27, 28, 30], reason that could partially explain the 
discrepancy observed among the different works. Thus, 
to bypass this impasse and achieve a clearer view of the 
data, we consider different cut-off of positivity, according 
to literature and in particular 1%, 10% or IRS [16-22, 27, 
28, 30]. The AR cut-off point of 10% in primary ovarian 
lesion seems to be the best predictor of brain progression 
in EOC patients. Therefore, EOC primary tumors that 
express AR are lower prone to cerebral spread. This 
observation may be in agreement with other recent studies 
stressing the favourable prognostic role of AR identifying 
a subgroup of patients with better survival in ovarian, 
breast and endometrial cancers, founding the basis to an 
endocrine anti-AR therapeutic approach [27, 28, 31-33].
In our study, a low or none tumor expression of 
HER2 identifies a subgroup of EOC patients with higher 
risk to develop brain metastases even if with a borderline 
statistical significance, probably related to the small 
number of analysed cases. In general, very few data 
are reported in literature regarding HER2 prognostic/
predictive role in EOC, although its overexpression seems 
to be related to worse patient’s outcome [30, 34, 35]. In 
this setting, our observation could seem in contrast with 
previously reports [26, 30, 34, 35], but we might speculate 
that as brain progression represent a rare and late event in 
EOC natural history [13], it could be possible that patients 
with HER2 overexpression die before brain metastatic 
dissemination.
Almost no data are reported in literature about 
protein expression profile assessment in brain metastases 
from EOC: the only, to our knowledge, is the paper by 
Yoshida et al. including a single case of matched primary 
and metastatic lesion [36]. The reason for this scarcity 
may rely on both the rarity of the event and of the surgery, 
as only 30% of patients [3, 13] undergo brain metastatic 
resection. Thus, our paper is the first reported work that 
focused on investigation of protein expression profile in 
a consecutive case series of EOC and their matched brain 
metastases. Considering hormone receptors status as 
continuous variables, we observed a significant difference 
between primary and brain lesions in expressing 
ER(57.4% vs. 34%, p=0.013) and AR (16.9% vs. 6.8%, 
p=0.032). Specifically, a reduction of both receptors has 
been detected in metastatic tissue. Since CNS progression 
is clearly an adverse prognostic feature, our results are 
consistent with previously reported good prognostic role 
of AR, as the tumors seem to lose AR protein expression 
during the metastatic spread to brain. A progressive ‘de-
differentiation’ of neoplastic cells could be hypothesized.
In conclusion, the increased incidence of CNS 
metastases from EOC underlines the importance of 
identifying predictive biomarkers tightly associated with 
CNS progression. The identification of patients at higher 
risk to develop CNS metastases may help to improve 
prognosis and quality of life, as previously extensively 
reported [3, 4, 6, 8, 10, 11, 13]. Although the present case-
control study is the biggest ever reported in literature, in 
terms the number of enrolled patients and the possibility 
to analyse EOC and their matched brain metastasis, a 
validation in larger series is likely.
MATERIALS AND METHODS
Patient’s collection
From a consecutive, retrospective and multi-
institutional series of 1092 patients who underwent 
surgery for brain metastases resection between January 
1998 and December 2013, a cohort of 24 patients with 
CNS metastases developed from a primary, histologically 
confirmed EOC was extrapolated. The initial cohort was 
retrieved from the Pathology archives of the Hospitals 
included in the Neuro-Oncological Network of the 
Piedmont Region-Italy (AOU Città della Salute e della 
Scienza of Turin, AO San Giovanni Bosco Hospital 
of Turin, AOU Maggiore della Carità of Novara, AO 
S.Croce e Carle Hospital of Cuneo, AO SS. Antonio, 
Biagio and Cesare Arrigo of Alessandria). Essential 
inclusion criteria for the study were the availability of 
both i) paraffin-embedded tissue blocks (corresponding to 
primary ovarian lesion and its matched brain metastasis) 
and ii) follow-up data, thus 13/24 cases were excluded; 
therefore, a series of 11 patients was finally collected 
representing our “Case dataset”. For each patient, clinico-
histopathological data were obtained by medical records. 
The following parameters were recorded: i) age at 
diagnosis; ii) date of primary tumor and CNS metastasis 
diagnosis; iii) morphological features of ovarian and brain 
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metastasis as tumor histotype and grade (according to 
World Health Organization Classification of Tumours of 
Female Reproductive Organs, 4th Edition); iv) date and 
site of first relapse, v) type of patient’s treatment; vi) date 
of death or last follow up (FU). OS was determined as the 
time from the date of EOC diagnosis to the date of patient 
death or last FU, whereas progression free survival (PFS) 
as the time from the EOC diagnosis to the date of first 
clinical relapse. In addition, we calculated the Progression 
Brain Metastasis Free Survival (bPFS) as the time 
from the date of ovarian cancer first diagnosis to brain 
metastasis, and the Brain Metastasis Overall Survival 
(bOS) as the time from the date of brain metastasis 
diagnosis to death or last FU.
For comparison, we evaluated a second series of 22 
cases, named “Control dataset”, extracted from the clinical 
records of Candiolo Cancer Institute, including patients 
with a diagnosis of ovarian cancer who had not developed 
brain metastasis after a median FU of 38,5 months (range 
6-82 months). In order to statistically compare the two 
subgroups and to avoid confounders, Cases were paired 
with Controls with a 1:2 ratio, according to the following 
three clinico-pathological parameters: tumor grade, 
clinical tumor stage and residual disease after surgery 
(present vs. absent). The same clinico-morphological 
features collected for the Case dataset were also obtained 
for this subgroup of patients.
The study was submitted to and approved by the 
Ethic Institutional Review Board for “Biobanking and 
use of human tissues for experimental studies” of the 
Pathology Service of the AOU Città della Salute e della 
Scienza (Turin, Italy). The project provided a verbal 
and not written informed consent from the patients due 
to the retrospective approach of the study, which did not 
impact on their treatment. All the cases were anonymously 
recorded. The Institutional Review Board approved this 
consent procedure.
Immunohistochemistry procedures
The most representative paraffin block was selected 
for each lesion and immune-histochemistry was performed 
in all cases. Three-micrometer-thick serial paraffin sections 
were prepared and routinely stained with Hematoxylin and 
Eosin (H&E); additional sections, collected on superfrost 
plus slides, were used for immune-histochemical analysis. 
Immune-histochemical reactions using antibodies anti-ER 
(monoclonal antibody, clone SP1, pre-diluted, Ventana, 
Roche); anti-PR (monoclonal antibody, clone 16, diluted 
1:100, Novocastra™ Leica); anti-AR (monoclonal 
antibody, clone SP107, pre-diluted, Ventana, Roche), and 
anti-HER2 (rabbit monoclonal antibody, clone 4B5, pre-
diluted, Ventana, Roche) were performed in an automated 
immunostainer (VentanaBenchMark XT AutoStainer, 
Ventana Medical Systems, Tucson, AZ, USA). Appropriate 
positive and negative controls were included for each 
immune-histochemical run.
Staining interpretation
Two observers, who were blinded to clinical data, 
independently evaluated the staining results. Hormone 
receptors were considered as follows: i) continue variable 
(number of positive neoplastic cells considered as a 
percentage ranging from 0 to 100%), ii) discrete variable 
using cut-off of 1% [30, 31, 37] and 10% [16, 17, 22, 
27, 28, 38] as previously reported in literature, and iii) 
dichotomised variable according to the recently reported 
Immunoreactive Score (IRS) [18-21]. HER2 status was 
assessed according to ASCO/CAP recommendations 
(2013) for breast cancer [39].
Statistical analysis
All statistical analyses were performed using SPSS 
software for Windows (version 22.0; SPSS Inc., Chicago, 
IL). Quantitative variables were initially compared with 
Pearson Chi-square test, but due to the small number of 
cases results are not reliable. Therefore Fisher exact test 
has been considered for the further statistical analyses. 
Qualitative variables were compared using analysis of 
variance (ANOVA) or dependent T test for paired samples. 
Multivariate analysis was performed using regression 
analysis. P values <0.05 were considered significant, and 
all tests were two-tailed.
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